A study published in Nature Microbiology now shows for the first time that Candida auris uses a CO₂-based metabolic strategy to survive in the nutrient-poor conditions of the skin and to better tolerate antifungal therapies – especially amphotericin B (AMB).24. Dezember 2025
News Smith+Nephew improves evidence generation by aligning clinical and medical affairsHealthradar8. September 2025 The importance of collaboration The successful development and launch of new devices are dependent on strong cross-functional collaboration across clinical…
